The Great Illusion of Measurability in Business

The recent announcement by BigPharma Inc. that it will adopt a new method for tracking quarterly earnings has sent shockwaves through Wall Street. At first glance, this seems like a positive development – after all, who wouldn’t want to have a better sense of their company’s financial health? However, scratch beneath the surface and it becomes clear that this move is not as revolutionary as it initially appears.

Behind the scenes, BigPharma has been working with McKinsey & Company consultants to implement a new metrics system. This system uses advanced algorithms to take into account factors such as supply chain disruptions and social media sentiment analysis. The company claims this will provide a more accurate picture of its financial health.

Measurability is a dirty word in business, where the notion that everything can be measured has led to absurdity. Companies have become obsessed with quantifying intangibles, from employee “happiness” through forced surveys to tracking the ROI on team-building exercises. This fixation on metrics has distracted companies from more pressing issues.

The real purpose of these new metrics is to give CEOs a sense of control in an increasingly unpredictable world. However, no amount of data can prepare you for the unexpected. Ask anyone who’s been affected by a global pandemic or economic downturn – they’ll tell you that it’s not about having the right numbers, but being prepared to adapt.

BigPharma’s new metrics system is just the latest iteration in this trend. While it may provide some benefits, its true cost will likely be passed on to consumers through higher prices for prescription medications. Investors should be wary of this trend and question what drives companies’ obsession with measurability.

Is it a genuine desire for accountability or simply a convenient excuse for companies to justify their bloated executive suites? We’ve seen this movie before – the dot-com bubble of the early 2000s was all about “disrupting” traditional business models through fancy new metrics and buzzwords. This trend is repeating itself, and it’s time someone blew the whistle.

BigPharma’s future is uncertain, but one thing’s clear: investors should keep a close eye on this company and not get caught up in the hype surrounding its new metrics system.